Physician profile
Frank Morris
NPI 1891789988
$5,765.71
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,485 · 2020: $367 · 2021: $533 · 2022: $1,061 · 2023: $1,738 · 2024: $581.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,319.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,319.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $776.24 | 2019-2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $747.32 | 2019-2024 | Eliquis, Camzyos |
| Medtronic, INC. | $613.56 | 2021-2024 | Onyx Frontier |
| Novartis Pharmaceuticals Corporation | $524.29 | 2019-2024 | |
| Abbott Laboratories | $460.55 | 2022-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Gallant |
| Edwards Lifesciences Corporation | $308.06 | 2019 | |
| Boston Scientific Corporation | $288.26 | 2019-2023 | Watchman |
| Amgen INC. | $282.12 | 2019-2024 | Repatha |
| Pfizer INC. | $268.28 | 2019-2024 | |
| Gilead Sciences, INC. | $222.02 | 2019 | |
| Scpharmaceuticals INC. | $212.74 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $145.44 | 2022-2024 | Farxiga, Brilinta |
| Kowa Pharmaceuticals America, INC. | $135.56 | 2019-2021 | |
| Abiomed | $113.91 | 2020 | |
| Merck Sharp & Dohme LLC | $110.05 | 2022-2024 | Verquvo |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $98.59 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Atricure, INC. | $93.62 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $69.63 | 2024 | |
| Janssen Pharmaceuticals, INC | $48.78 | 2023 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $41.93 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $36.77 | 2023 | Nexletol |
| Irhythm Technologies, INC. | $32.34 | 2020-2023 | Zio Xt Patch |
| Sanofi-Aventis U.S. LLC | $31.24 | 2019-2023 | |
| Daiichi Sankyo INC. | $29.85 | 2024 | Injectafer |
| Akcea Therapeutics, INC. | $21.37 | 2020 | |
| Amarin Pharma, INC. | $20.43 | 2019 | |
| Azurity Pharmaceuticals, INC. | $18.83 | 2023 | Edarbi |
| Regeneron Healthcare Solutions, INC. | $13.93 | 2023 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Frank Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.